You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameMefloquine
Accession NumberDB00358  (APRD00300)
TypeSmall Molecule
GroupsApproved
DescriptionA phospholipid-interacting antimalarial drug (antimalarials). It is very effective against plasmodium falciparum with very few side effects. [PubChem]
Structure
Thumb
Synonyms
[(R*,S*)-2,8-bis(trifluoromethyl)quinolin-4-yl]-(2-piperidyl)methanol
alpha-2-Piperidinyl-2,8-bis(trifluoromethyl)-4-quinolinemethanol
Mefloquin
Mefloquina
Méfloquine
Mefloquine
Mefloquinum
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Lariam Tab 250mgtablet250 mgoralHoffmann La Roche Limited1993-12-312013-05-02Canada
Mefloquinetablet250 mgoralAa Pharma Inc2002-07-23Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Mefloquine Hydrochloridetablet250 mg/1oralPhysicians Total Care, Inc.2005-09-26Not applicableUs
Mefloquine Hydrochloridetablet250 mg/1oralRoxane Laboratories, Inc.2004-10-01Not applicableUs
Mefloquine Hydrochloridetablet250 mg/1oralRebel Distributors Corp2003-12-29Not applicableUs
Mefloquine Hydrochloridetablet250 mg/1oralWest ward Pharmaceutical Corp2010-04-21Not applicableUs
Mefloquine Hydrochloridetablet250 mg/1oralRebel Distributors Corp2010-04-21Not applicableUs
Mefloquine Hydrochloridetablet250 mg/1oralBarr Laboratories Inc.2004-01-06Not applicableUs
Mefloquine Hydrochloridetablet250 mg/1oralH.J. Harkins Company, Inc.2010-04-21Not applicableUs
Mefloquine Hydrochloridetablet250 mg/1oralSandoz Inc2002-02-202016-03-31Us
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
EloquineUnifarm
FacitalZydus Cadila
FalcitalCadila HC
LariamHoffmann–La Roche
LarimefIpca
MefaxAlkem
MefliamCipla Medpro
MeflonACI
MefloquinaAC Farma
MefqueZydus Cadila
MephaquinHisamitsu Seiyaku
Mephaquin LactabMepha
MequinAtlantic
MqfSun
SutonNewai Chem
TropicurInvesti
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Mefloquine Hydrochloride
Thumb
  • InChI Key: WESWYMRNZNDGBX-YLCXCWDSSA-N
  • Monoisotopic Mass: 414.093360113
  • Average Mass: 414.773
DBSALT000311
Categories
UNIITML814419R
CAS number53230-10-7
WeightAverage: 378.3122
Monoisotopic: 378.116682374
Chemical FormulaC17H16F6N2O
InChI KeyInChIKey=XEEQGYMUWCZPDN-UHFFFAOYSA-N
InChI
InChI=1S/C17H16F6N2O/c18-16(19,20)11-5-3-4-9-10(15(26)12-6-1-2-7-24-12)8-13(17(21,22)23)25-14(9)11/h3-5,8,12,15,24,26H,1-2,6-7H2
IUPAC Name
[2,8-bis(trifluoromethyl)quinolin-4-yl](piperidin-2-yl)methanol
SMILES
OC(C1CCCCN1)C1=CC(=NC2=C1C=CC=C2C(F)(F)F)C(F)(F)F
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as quinolines and derivatives. These are compounds containing a quinoline moiety, which consists of a benzene ring fused to a pyrimidine ring to form benzo[b]azabenzene.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassQuinolines and derivatives
Sub ClassNot Available
Direct ParentQuinolines and derivatives
Alternative Parents
Substituents
  • Quinoline
  • Aralkylamine
  • Benzenoid
  • Pyridine
  • Piperidine
  • Heteroaromatic compound
  • Secondary alcohol
  • 1,2-aminoalcohol
  • Azacycle
  • Secondary amine
  • Secondary aliphatic amine
  • Hydrocarbon derivative
  • Aromatic alcohol
  • Organooxygen compound
  • Organonitrogen compound
  • Organofluoride
  • Organohalogen compound
  • Amine
  • Alkyl halide
  • Alkyl fluoride
  • Alcohol
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationFor the treatment of mild to moderate acute malaria caused by Mefloquineuine-susceptible strains of Plasmodium falciparum (both chloroquine-susceptible and resistant strains) or by Plasmodium vivax. Also for the prophylaxis of Plasmodium falciparum and Plasmodium vivax malaria infections, including prophylaxis of chloroquine-resistant strains of Plasmodium falciparum.
PharmacodynamicsMefloquine is an antimalarial agent which acts as a blood schizonticide. Mefloquine is active against the erythrocytic stages of Plasmodium species. However, the drug has no effect against the exoerythrocytic (hepatic) stages of the parasite. Mefloquine is effective against malaria parasites resistant to chloroquine. Mefloquine is a chiral molecule. According to some research, the (+) enantiomer is more effective in treating malaria, and the (-) enantiomer specifically binds to adenosine receptors in the central nervous system, which may explain some of its psychotropic effects.
Mechanism of actionMefloquine has been found to produce swelling of the Plasmodium falciparum food vacuoles. It may act by forming toxic complexes with free heme that damage membranes and interact with other plasmodial components.
Related Articles
AbsorptionWell absorbed from the gastrointestinal tract. The presence of food significantly enhances the rate and extent of absorption.
Volume of distribution
  • 20 L/kg [healthy adults]
Protein binding98%
Metabolism

Hepatic. Two metabolites have been identified in humans. The main metabolite, 2,8-bis-trifluoromethyl-4-quinoline carboxylic acid, is inactive against Plasmodium falciparum. The second metabolite, an alcohol, is present in minute quantities.

SubstrateEnzymesProduct
Mefloquine
Not Available
2,8-bis-trifluoromethyl-4-quinoline carboxylic acidDetails
Route of eliminationThere is evidence that mefloquine is excreted mainly in the bile and feces. Urinary excretion of unchanged mefloquine and its main metabolite under steady-state condition accounted for about 9% and 4% of the dose, respectively.
Half life2 to 4 weeks
Clearance
  • 30 mL/min
ToxicityOral, rat: LD50 = 880 mg/kg. Symptoms of overdose include nausea, vomiting, and weight loss.
Affected organisms
  • Plasmodium
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9959
Blood Brain Barrier+0.9445
Caco-2 permeable-0.5753
P-glycoprotein substrateSubstrate0.6796
P-glycoprotein inhibitor INon-inhibitor0.7395
P-glycoprotein inhibitor IIInhibitor0.5419
Renal organic cation transporterNon-inhibitor0.6446
CYP450 2C9 substrateNon-substrate0.8711
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateNon-substrate0.6524
CYP450 1A2 substrateInhibitor0.9107
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorInhibitor0.8931
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorNon-inhibitor0.8533
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9163
Ames testNon AMES toxic0.809
CarcinogenicityNon-carcinogens0.9437
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.9133 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9035
hERG inhibition (predictor II)Inhibitor0.8204
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Hoffmann la roche inc
  • Barr laboratories inc
  • Roxane laboratories inc
  • Sandoz inc
  • United states army walter reed army institute research
  • West ward pharmaceutical corp
Packagers
Dosage forms
FormRouteStrength
Tabletoral250 mg
Tabletoral250 mg/1
Prices
Unit descriptionCostUnit
Lariam 25 250 mg tablet Box322.77USD box
Lariam 250 mg tablet12.41USD tablet
Mefloquine hcl 250 mg tablet10.8USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
water solubility5000 mg/L (HCl salt)Not Available
logP3.9Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.038 mg/mLALOGPS
logP3.1ALOGPS
logP4.11ChemAxon
logS-4ALOGPS
pKa (Strongest Acidic)13.79ChemAxon
pKa (Strongest Basic)9.46ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area45.15 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity82.58 m3·mol-1ChemAxon
Polarizability31.73 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

DrugSyn.org

US4507482
General ReferencesNot Available
External Links
ATC CodesP01BF02P01BC02
AHFS Codes
  • 08:30.08
PDB Entries
FDA labelDownload (394 KB)
MSDSDownload (107 KB)
Interactions
Drug Interactions
Drug
2-Aminobenzoic AcidThe therapeutic efficacy of 2-Aminobenzoic Acid can be decreased when used in combination with Mefloquine.
4-AndrostenedioneThe risk or severity of adverse effects can be increased when 4-Androstenedione is combined with Mefloquine.
7-NitroindazoleThe therapeutic efficacy of 7-Nitroindazole can be decreased when used in combination with Mefloquine.
AcebutololMefloquine may increase the bradycardic activities of Acebutolol.
AcepromazineThe serum concentration of Acepromazine can be increased when it is combined with Mefloquine.
AcetaminophenThe serum concentration of Acetaminophen can be increased when it is combined with Mefloquine.
AcetazolamideThe therapeutic efficacy of Acetazolamide can be decreased when used in combination with Mefloquine.
AcetylcholineThe risk or severity of adverse effects can be increased when Mefloquine is combined with Acetylcholine.
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Mefloquine.
AclidiniumThe therapeutic efficacy of Aclidinium can be decreased when used in combination with Mefloquine.
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Mefloquine.
AlclometasoneThe risk or severity of adverse effects can be increased when Alclometasone is combined with Mefloquine.
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Mefloquine.
AldosteroneThe risk or severity of adverse effects can be increased when Aldosterone is combined with Mefloquine.
AlimemazineThe serum concentration of Alimemazine can be increased when it is combined with Mefloquine.
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Mefloquine.
AlprenololMefloquine may increase the bradycardic activities of Alprenolol.
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Mefloquine.
AmcinonideThe risk or severity of adverse effects can be increased when Amcinonide is combined with Mefloquine.
AmiodaroneThe metabolism of Mefloquine can be decreased when combined with Amiodarone.
AmiodaroneMefloquine may increase the QTc-prolonging activities of Amiodarone.
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Mefloquine.
AmodiaquineThe risk or severity of adverse effects can be increased when Amodiaquine is combined with Mefloquine.
AnagrelideMefloquine may increase the QTc-prolonging activities of Anagrelide.
Anisotropine MethylbromideThe therapeutic efficacy of Anisotropine Methylbromide can be decreased when used in combination with Mefloquine.
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Mefloquine.
AprepitantThe serum concentration of Mefloquine can be increased when it is combined with Aprepitant.
ArecolineThe risk or severity of adverse effects can be increased when Mefloquine is combined with Arecoline.
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Mefloquine.
ArotinololMefloquine may increase the bradycardic activities of Arotinolol.
Arsenic trioxideThe serum concentration of Arsenic trioxide can be increased when it is combined with Mefloquine.
ArtemetherThe risk or severity of adverse effects can be increased when Artemether is combined with Mefloquine.
ArtemetherMefloquine may increase the QTc-prolonging activities of Artemether.
AsenapineMefloquine may increase the QTc-prolonging activities of Asenapine.
AtazanavirThe metabolism of Mefloquine can be decreased when combined with Atazanavir.
AtazanavirThe serum concentration of Atazanavir can be increased when it is combined with Mefloquine.
AtenololMefloquine may increase the bradycardic activities of Atenolol.
AtomoxetineThe metabolism of Mefloquine can be decreased when combined with Atomoxetine.
Atracurium besylateThe therapeutic efficacy of Atracurium besylate can be decreased when used in combination with Mefloquine.
AtropineThe therapeutic efficacy of Atropine can be decreased when used in combination with Mefloquine.
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Mefloquine.
AzithromycinMefloquine may increase the QTc-prolonging activities of Azithromycin.
BarbexacloneThe therapeutic efficacy of Barbexaclone can be decreased when used in combination with Mefloquine.
BeclamideThe therapeutic efficacy of Beclamide can be decreased when used in combination with Mefloquine.
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Mefloquine.
BedaquilineMefloquine may increase the QTc-prolonging activities of Bedaquiline.
BefunololMefloquine may increase the bradycardic activities of Befunolol.
BenactyzineThe therapeutic efficacy of Benactyzine can be decreased when used in combination with Mefloquine.
BenzatropineThe therapeutic efficacy of Benzatropine can be decreased when used in combination with Mefloquine.
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Mefloquine.
BetamethasoneThe risk or severity of adverse effects can be increased when Betamethasone is combined with Mefloquine.
BetaxololMefloquine may increase the bradycardic activities of Betaxolol.
BethanecholThe risk or severity of adverse effects can be increased when Mefloquine is combined with Bethanechol.
BevantololMefloquine may increase the bradycardic activities of Bevantolol.
BexaroteneThe serum concentration of Mefloquine can be decreased when it is combined with Bexarotene.
BiperidenThe therapeutic efficacy of Biperiden can be decreased when used in combination with Mefloquine.
BisoprololMefloquine may increase the bradycardic activities of Bisoprolol.
BoceprevirThe metabolism of Mefloquine can be decreased when combined with Boceprevir.
BoceprevirThe serum concentration of Boceprevir can be increased when it is combined with Mefloquine.
BopindololMefloquine may increase the bradycardic activities of Bopindolol.
BortezomibThe metabolism of Mefloquine can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Mefloquine can be decreased when it is combined with Bosentan.
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Mefloquine.
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Mefloquine.
BrivaracetamThe therapeutic efficacy of Brivaracetam can be decreased when used in combination with Mefloquine.
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Mefloquine.
BudesonideThe risk or severity of adverse effects can be increased when Budesonide is combined with Mefloquine.
BufuralolMefloquine may increase the bradycardic activities of Bufuralol.
BupranololMefloquine may increase the bradycardic activities of Bupranolol.
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Mefloquine.
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Mefloquine.
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Mefloquine.
CanagliflozinThe serum concentration of Canagliflozin can be increased when it is combined with Mefloquine.
CarbacholThe risk or severity of adverse effects can be increased when Mefloquine is combined with Carbachol.
CarbamazepineThe metabolism of Mefloquine can be increased when combined with Carbamazepine.
CarbamazepineThe serum concentration of Carbamazepine can be increased when it is combined with Mefloquine.
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Mefloquine.
CarteololMefloquine may increase the bradycardic activities of Carteolol.
CarvedilolMefloquine may increase the bradycardic activities of Carvedilol.
CeliprololMefloquine may increase the bradycardic activities of Celiprolol.
CeritinibThe serum concentration of Mefloquine can be increased when it is combined with Ceritinib.
CeritinibMefloquine may increase the QTc-prolonging activities of Ceritinib.
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Mefloquine.
CevimelineThe risk or severity of adverse effects can be increased when Mefloquine is combined with Cevimeline.
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Mefloquine.
ChloroquineMefloquine may increase the QTc-prolonging activities of Chloroquine.
ChlorphenoxamineThe therapeutic efficacy of Chlorphenoxamine can be decreased when used in combination with Mefloquine.
ChlorpromazineThe serum concentration of Chlorpromazine can be increased when it is combined with Mefloquine.
CiclesonideThe risk or severity of adverse effects can be increased when Ciclesonide is combined with Mefloquine.
CimetidineThe serum concentration of Cimetidine can be increased when it is combined with Mefloquine.
CiprofloxacinMefloquine may increase the QTc-prolonging activities of Ciprofloxacin.
CisaprideMefloquine may increase the QTc-prolonging activities of Cisapride.
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Mefloquine.
CitalopramThe serum concentration of Citalopram can be increased when it is combined with Mefloquine.
ClarithromycinMefloquine may increase the QTc-prolonging activities of Clarithromycin.
ClarithromycinThe metabolism of Mefloquine can be decreased when combined with Clarithromycin.
ClemastineThe metabolism of Mefloquine can be decreased when combined with Clemastine.
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Mefloquine.
Clobetasol propionateThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Mefloquine.
ClocortoloneThe risk or severity of adverse effects can be increased when Clocortolone is combined with Mefloquine.
clomethiazoleThe therapeutic efficacy of clomethiazole can be decreased when used in combination with Mefloquine.
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Mefloquine.
ClonazepamThe therapeutic efficacy of Clonazepam can be decreased when used in combination with Mefloquine.
ClonidineThe serum concentration of Clonidine can be increased when it is combined with Mefloquine.
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Mefloquine.
ClorazepateThe therapeutic efficacy of Clorazepate can be decreased when used in combination with Mefloquine.
ClotrimazoleThe metabolism of Mefloquine can be decreased when combined with Clotrimazole.
ClozapineMefloquine may increase the QTc-prolonging activities of Clozapine.
CobicistatThe metabolism of Mefloquine can be decreased when combined with Cobicistat.
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Mefloquine.
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Mefloquine.
ConivaptanThe serum concentration of Mefloquine can be increased when it is combined with Conivaptan.
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Mefloquine.
Cortisone acetateThe risk or severity of adverse effects can be increased when Cortisone acetate is combined with Mefloquine.
CrizotinibMefloquine may increase the QTc-prolonging activities of Crizotinib.
CrizotinibThe metabolism of Mefloquine can be decreased when combined with Crizotinib.
CyclopentolateThe therapeutic efficacy of Cyclopentolate can be decreased when used in combination with Mefloquine.
CyclosporineThe metabolism of Mefloquine can be decreased when combined with Cyclosporine.
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Mefloquine.
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be increased when it is combined with Mefloquine.
DabrafenibThe serum concentration of Mefloquine can be decreased when it is combined with Dabrafenib.
DabrafenibThe serum concentration of Dabrafenib can be increased when it is combined with Mefloquine.
DactinomycinThe serum concentration of Dactinomycin can be increased when it is combined with Mefloquine.
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Mefloquine.
DapsoneThe risk or severity of adverse effects can be increased when Mefloquine is combined with Dapsone.
DarifenacinThe therapeutic efficacy of Darifenacin can be decreased when used in combination with Mefloquine.
DarunavirThe metabolism of Mefloquine can be decreased when combined with Darunavir.
DasatinibThe serum concentration of Mefloquine can be increased when it is combined with Dasatinib.
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Mefloquine.
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Mefloquine.
DeferasiroxThe serum concentration of Mefloquine can be decreased when it is combined with Deferasirox.
DehydroepiandrosteroneThe risk or severity of adverse effects can be increased when Dehydroepiandrosterone is combined with Mefloquine.
dehydroepiandrosterone sulfateThe risk or severity of adverse effects can be increased when dehydroepiandrosterone sulfate is combined with Mefloquine.
DelavirdineThe metabolism of Mefloquine can be decreased when combined with Delavirdine.
DelorazepamThe therapeutic efficacy of Delorazepam can be decreased when used in combination with Mefloquine.
deramciclaneThe therapeutic efficacy of deramciclane can be decreased when used in combination with Mefloquine.
DesloratadineThe therapeutic efficacy of Desloratadine can be decreased when used in combination with Mefloquine.
DesoximetasoneThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Mefloquine.
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Desoxycorticosterone acetate is combined with Mefloquine.
DexamethasoneThe serum concentration of Mefloquine can be decreased when it is combined with Dexamethasone.
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Mefloquine.
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Dexamethasone isonicotinate is combined with Mefloquine.
DexetimideThe therapeutic efficacy of Dexetimide can be decreased when used in combination with Mefloquine.
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Mefloquine.
DicyclomineThe therapeutic efficacy of Dicyclomine can be decreased when used in combination with Mefloquine.
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Mefloquine.
DiflorasoneThe risk or severity of adverse effects can be increased when Diflorasone is combined with Mefloquine.
DifluocortoloneThe risk or severity of adverse effects can be increased when Difluocortolone is combined with Mefloquine.
DifluprednateThe risk or severity of adverse effects can be increased when Difluprednate is combined with Mefloquine.
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Mefloquine.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Mefloquine.
DihydroergotamineThe metabolism of Mefloquine can be decreased when combined with Dihydroergotamine.
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Mefloquine.
DiltiazemThe metabolism of Mefloquine can be decreased when combined with Diltiazem.
DiltiazemThe serum concentration of Diltiazem can be increased when it is combined with Mefloquine.
DipyridamoleThe therapeutic efficacy of Mefloquine can be decreased when used in combination with Dipyridamole.
DipyridamoleThe serum concentration of Dipyridamole can be increased when it is combined with Mefloquine.
DisopyramideMefloquine may increase the QTc-prolonging activities of Disopyramide.
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Mefloquine.
DofetilideMefloquine may increase the QTc-prolonging activities of Dofetilide.
DolasetronMefloquine may increase the QTc-prolonging activities of Dolasetron.
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Mefloquine.
DoramectinThe therapeutic efficacy of Doramectin can be decreased when used in combination with Mefloquine.
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Mefloquine.
DoxycyclineThe metabolism of Mefloquine can be decreased when combined with Doxycycline.
DronedaroneThe metabolism of Mefloquine can be decreased when combined with Dronedarone.
DronedaroneMefloquine may increase the QTc-prolonging activities of Dronedarone.
DroperidolMefloquine may increase the QTc-prolonging activities of Droperidol.
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Mefloquine.
EfavirenzThe serum concentration of Mefloquine can be decreased when it is combined with Efavirenz.
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Mefloquine.
EliglustatMefloquine may increase the QTc-prolonging activities of Eliglustat.
EnzalutamideThe serum concentration of Mefloquine can be decreased when it is combined with Enzalutamide.
EperisoneThe therapeutic efficacy of Eperisone can be decreased when used in combination with Mefloquine.
EPIBATIDINEThe risk or severity of adverse effects can be increased when Mefloquine is combined with EPIBATIDINE.
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Mefloquine.
EquileninThe risk or severity of adverse effects can be increased when Equilenin is combined with Mefloquine.
EquilinThe risk or severity of adverse effects can be increased when Equilin is combined with Mefloquine.
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Mefloquine.
ErythromycinMefloquine may increase the QTc-prolonging activities of Erythromycin.
ErythromycinThe metabolism of Mefloquine can be decreased when combined with Erythromycin.
EscitalopramMefloquine may increase the QTc-prolonging activities of Escitalopram.
Eslicarbazepine acetateThe therapeutic efficacy of Eslicarbazepine acetate can be decreased when used in combination with Mefloquine.
Eslicarbazepine acetateThe serum concentration of Mefloquine can be decreased when it is combined with Eslicarbazepine acetate.
EsmololMefloquine may increase the bradycardic activities of Esmolol.
EstazolamThe therapeutic efficacy of Estazolam can be decreased when used in combination with Mefloquine.
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Mefloquine.
EstriolThe serum concentration of Estriol can be increased when it is combined with Mefloquine.
EstroneThe serum concentration of Estrone can be increased when it is combined with Mefloquine.
EstroneThe risk or severity of adverse effects can be increased when Estrone is combined with Mefloquine.
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Mefloquine.
EthopropazineThe therapeutic efficacy of Ethopropazine can be decreased when used in combination with Mefloquine.
EthosuximideThe therapeutic efficacy of Ethosuximide can be decreased when used in combination with Mefloquine.
EthotoinThe therapeutic efficacy of Ethotoin can be decreased when used in combination with Mefloquine.
EtoposideThe serum concentration of Etoposide can be increased when it is combined with Mefloquine.
EtravirineThe serum concentration of Mefloquine can be decreased when it is combined with Etravirine.
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Mefloquine.
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Mefloquine.
EzogabineThe therapeutic efficacy of Ezogabine can be decreased when used in combination with Mefloquine.
FelbamateThe therapeutic efficacy of Felbamate can be decreased when used in combination with Mefloquine.
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Mefloquine.
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Mefloquine.
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Mefloquine.
FlecainideMefloquine may increase the QTc-prolonging activities of Flecainide.
FluconazoleThe metabolism of Mefloquine can be decreased when combined with Fluconazole.
FludiazepamThe therapeutic efficacy of Fludiazepam can be decreased when used in combination with Mefloquine.
FludrocortisoneThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Mefloquine.
FlumethasoneThe risk or severity of adverse effects can be increased when Flumethasone is combined with Mefloquine.
FlunarizineThe therapeutic efficacy of Flunarizine can be decreased when used in combination with Mefloquine.
FlunisolideThe risk or severity of adverse effects can be increased when Flunisolide is combined with Mefloquine.
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Mefloquine.
FluocinonideThe risk or severity of adverse effects can be increased when Fluocinonide is combined with Mefloquine.
FluocortoloneThe risk or severity of adverse effects can be increased when Fluocortolone is combined with Mefloquine.
FluorometholoneThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Mefloquine.
FluoxetineMefloquine may increase the QTc-prolonging activities of Fluoxetine.
FlupentixolMefloquine may increase the QTc-prolonging activities of Flupentixol.
FluphenazineThe serum concentration of Fluphenazine can be increased when it is combined with Mefloquine.
FluprednideneThe risk or severity of adverse effects can be increased when Fluprednidene is combined with Mefloquine.
FluprednisoloneThe risk or severity of adverse effects can be increased when Fluprednisolone is combined with Mefloquine.
FlurandrenolideThe risk or severity of adverse effects can be increased when Flurandrenolide is combined with Mefloquine.
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Mefloquine.
Fluticasone furoateThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Mefloquine.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Mefloquine.
FluvoxamineThe metabolism of Mefloquine can be decreased when combined with Fluvoxamine.
FosamprenavirThe metabolism of Mefloquine can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Mefloquine can be increased when it is combined with Fosaprepitant.
FosphenytoinThe therapeutic efficacy of Fosphenytoin can be decreased when used in combination with Mefloquine.
FosphenytoinThe metabolism of Mefloquine can be increased when combined with Fosphenytoin.
Fusidic AcidThe serum concentration of Mefloquine can be increased when it is combined with Fusidic Acid.
GabapentinThe therapeutic efficacy of Gabapentin can be decreased when used in combination with Mefloquine.
GaboxadolThe therapeutic efficacy of Gaboxadol can be decreased when used in combination with Mefloquine.
Gadobenic acidMefloquine may increase the QTc-prolonging activities of Gadobenic acid.
Gallamine TriethiodideThe therapeutic efficacy of Gallamine Triethiodide can be decreased when used in combination with Mefloquine.
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Mefloquine.
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Mefloquine.
GemifloxacinMefloquine may increase the QTc-prolonging activities of Gemifloxacin.
GlycopyrroniumThe therapeutic efficacy of Glycopyrronium can be decreased when used in combination with Mefloquine.
GoserelinMefloquine may increase the QTc-prolonging activities of Goserelin.
GranisetronMefloquine may increase the QTc-prolonging activities of Granisetron.
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Mefloquine.
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Mefloquine.
GTS-21The risk or severity of adverse effects can be increased when Mefloquine is combined with GTS-21.
HalofantrineMefloquine may increase the QTc-prolonging activities of Halofantrine.
HaloperidolMefloquine may increase the QTc-prolonging activities of Haloperidol.
HexamethoniumThe therapeutic efficacy of Hexamethonium can be decreased when used in combination with Mefloquine.
HomatropineThe therapeutic efficacy of Homatropine can be decreased when used in combination with Mefloquine.
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Mefloquine.
HydrocortisoneThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Mefloquine.
HydroxychloroquineThe risk or severity of adverse effects can be increased when Hydroxychloroquine is combined with Mefloquine.
HyoscyamineThe therapeutic efficacy of Hyoscyamine can be decreased when used in combination with Mefloquine.
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Mefloquine.
IbutilideMefloquine may increase the QTc-prolonging activities of Ibutilide.
IdelalisibThe serum concentration of Mefloquine can be increased when it is combined with Idelalisib.
IfenprodilThe therapeutic efficacy of Ifenprodil can be decreased when used in combination with Mefloquine.
IloperidoneMefloquine may increase the QTc-prolonging activities of Iloperidone.
ImatinibThe metabolism of Mefloquine can be decreased when combined with Imatinib.
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Mefloquine.
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Mefloquine.
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Mefloquine.
IndenololMefloquine may increase the bradycardic activities of Indenolol.
IndinavirThe metabolism of Mefloquine can be decreased when combined with Indinavir.
IndinavirThe serum concentration of Indinavir can be increased when it is combined with Mefloquine.
IndomethacinThe serum concentration of Indomethacin can be increased when it is combined with Mefloquine.
Ipratropium bromideThe therapeutic efficacy of Ipratropium bromide can be decreased when used in combination with Mefloquine.
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Mefloquine.
IsavuconazoniumThe metabolism of Mefloquine can be decreased when combined with Isavuconazonium.
IsradipineThe metabolism of Mefloquine can be decreased when combined with Isradipine.
ItraconazoleThe metabolism of Mefloquine can be decreased when combined with Itraconazole.
IvacaftorThe serum concentration of Mefloquine can be increased when it is combined with Ivacaftor.
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Mefloquine.
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Mefloquine.
KetoconazoleThe metabolism of Mefloquine can be decreased when combined with Ketoconazole.
KetoconazoleThe serum concentration of Ketoconazole can be increased when it is combined with Mefloquine.
LabetalolMefloquine may increase the bradycardic activities of Labetalol.
LacosamideThe therapeutic efficacy of Lacosamide can be decreased when used in combination with Mefloquine.
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Mefloquine.
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Mefloquine.
LansoprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Mefloquine.
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Mefloquine.
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Mefloquine.
LenvatinibMefloquine may increase the QTc-prolonging activities of Lenvatinib.
LeuprolideMefloquine may increase the QTc-prolonging activities of Leuprolide.
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Mefloquine.
LevofloxacinMefloquine may increase the QTc-prolonging activities of Levofloxacin.
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Mefloquine.
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Mefloquine.
LobelineThe risk or severity of adverse effects can be increased when Mefloquine is combined with Lobeline.
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Mefloquine.
LopinavirThe metabolism of Mefloquine can be decreased when combined with Lopinavir.
LopinavirMefloquine may increase the QTc-prolonging activities of Lopinavir.
LorazepamThe therapeutic efficacy of Lorazepam can be decreased when used in combination with Mefloquine.
LosartanThe serum concentration of Losartan can be increased when it is combined with Mefloquine.
LovastatinThe metabolism of Mefloquine can be decreased when combined with Lovastatin.
LuliconazoleThe serum concentration of Mefloquine can be increased when it is combined with Luliconazole.
LumefantrineThe risk or severity of adverse effects can be increased when Mefloquine is combined with Lumefantrine.
Magnesium SulfateThe therapeutic efficacy of Magnesium Sulfate can be decreased when used in combination with Mefloquine.
MannitolThe serum concentration of Mannitol can be increased when it is combined with Mefloquine.
MecamylamineThe therapeutic efficacy of Mecamylamine can be decreased when used in combination with Mefloquine.
MedrysoneThe risk or severity of adverse effects can be increased when Medrysone is combined with Mefloquine.
MelengestrolThe risk or severity of adverse effects can be increased when Melengestrol is combined with Mefloquine.
MephenytoinThe therapeutic efficacy of Mephenytoin can be decreased when used in combination with Mefloquine.
MeprobamateThe therapeutic efficacy of Meprobamate can be decreased when used in combination with Mefloquine.
MesoridazineThe serum concentration of Mesoridazine can be increased when it is combined with Mefloquine.
MethacholineThe risk or severity of adverse effects can be increased when Mefloquine is combined with Methacholine.
MethadoneMefloquine may increase the QTc-prolonging activities of Methadone.
MethanthelineThe therapeutic efficacy of Methantheline can be decreased when used in combination with Mefloquine.
MetharbitalThe therapeutic efficacy of Metharbital can be decreased when used in combination with Mefloquine.
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Mefloquine.
MethotrimeprazineThe serum concentration of Methotrimeprazine can be increased when it is combined with Mefloquine.
MethsuximideThe therapeutic efficacy of Methsuximide can be decreased when used in combination with Mefloquine.
Methylene blueThe serum concentration of Methylene blue can be increased when it is combined with Mefloquine.
MethylphenobarbitalThe therapeutic efficacy of Methylphenobarbital can be decreased when used in combination with Mefloquine.
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Mefloquine.
MethylprednisoloneThe risk or severity of adverse effects can be increased when Methylprednisolone is combined with Mefloquine.
MetixeneThe therapeutic efficacy of Metixene can be decreased when used in combination with Mefloquine.
MetoprololMefloquine may increase the bradycardic activities of Metoprolol.
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Mefloquine.
MifepristoneThe metabolism of Mefloquine can be decreased when combined with Mifepristone.
MifepristoneMefloquine may increase the QTc-prolonging activities of Mifepristone.
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Mefloquine.
MitotaneThe serum concentration of Mefloquine can be decreased when it is combined with Mitotane.
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Mefloquine.
MivacuriumMefloquine may decrease the neuromuscular blocking activities of Mivacurium.
ModafinilThe serum concentration of Mefloquine can be decreased when it is combined with Modafinil.
MometasoneThe risk or severity of adverse effects can be increased when Mometasone is combined with Mefloquine.
MoricizineThe serum concentration of Moricizine can be increased when it is combined with Mefloquine.
MorphineThe serum concentration of Morphine can be increased when it is combined with Mefloquine.
MoxifloxacinMefloquine may increase the QTc-prolonging activities of Moxifloxacin.
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Mefloquine.
N-butylscopolammonium bromideThe therapeutic efficacy of N-butylscopolammonium bromide can be decreased when used in combination with Mefloquine.
NadololMefloquine may increase the bradycardic activities of Nadolol.
NafcillinThe serum concentration of Mefloquine can be decreased when it is combined with Nafcillin.
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Mefloquine.
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Mefloquine.
NefazodoneThe metabolism of Mefloquine can be decreased when combined with Nefazodone.
NelfinavirThe metabolism of Mefloquine can be decreased when combined with Nelfinavir.
NelfinavirThe serum concentration of Nelfinavir can be increased when it is combined with Mefloquine.
NetupitantThe serum concentration of Mefloquine can be increased when it is combined with Netupitant.
NevirapineThe metabolism of Mefloquine can be decreased when combined with Nevirapine.
NicardipineThe serum concentration of Nicardipine can be increased when it is combined with Mefloquine.
NicotineThe risk or severity of adverse effects can be increased when Mefloquine is combined with Nicotine.
Nicotine bitartrateThe risk or severity of adverse effects can be increased when Mefloquine is combined with Nicotine bitartrate.
NifedipineThe serum concentration of Nifedipine can be increased when it is combined with Mefloquine.
NilotinibThe metabolism of Mefloquine can be decreased when combined with Nilotinib.
NilotinibThe serum concentration of Nilotinib can be increased when it is combined with Mefloquine.
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Mefloquine.
NitrazepamThe therapeutic efficacy of Nitrazepam can be decreased when used in combination with Mefloquine.
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Mefloquine.
NVA237The therapeutic efficacy of NVA237 can be decreased when used in combination with Mefloquine.
OfloxacinMefloquine may increase the QTc-prolonging activities of Ofloxacin.
OlanzapineThe serum concentration of Olanzapine can be increased when it is combined with Mefloquine.
OlaparibThe metabolism of Mefloquine can be decreased when combined with Olaparib.
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Mefloquine.
OndansetronMefloquine may increase the QTc-prolonging activities of Ondansetron.
OrphenadrineThe therapeutic efficacy of Orphenadrine can be decreased when used in combination with Mefloquine.
OsimertinibThe serum concentration of Mefloquine can be increased when it is combined with Osimertinib.
OxcarbazepineThe therapeutic efficacy of Oxcarbazepine can be decreased when used in combination with Mefloquine.
OxprenololMefloquine may increase the bradycardic activities of Oxprenolol.
OxybutyninThe therapeutic efficacy of Oxybutynin can be decreased when used in combination with Mefloquine.
OxyphenoniumThe therapeutic efficacy of Oxyphenonium can be decreased when used in combination with Mefloquine.
PaclitaxelThe serum concentration of Paclitaxel can be increased when it is combined with Mefloquine.
PalbociclibThe serum concentration of Mefloquine can be increased when it is combined with Palbociclib.
PaliperidoneMefloquine may increase the QTc-prolonging activities of Paliperidone.
PancuroniumThe therapeutic efficacy of Pancuronium can be decreased when used in combination with Mefloquine.
PanobinostatMefloquine may increase the QTc-prolonging activities of Panobinostat.
ParaldehydeThe therapeutic efficacy of Paraldehyde can be decreased when used in combination with Mefloquine.
ParamethadioneThe therapeutic efficacy of Paramethadione can be decreased when used in combination with Mefloquine.
ParamethasoneThe risk or severity of adverse effects can be increased when Paramethasone is combined with Mefloquine.
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Mefloquine.
PenbutololMefloquine may increase the bradycardic activities of Penbutolol.
PentamidineMefloquine may increase the QTc-prolonging activities of Pentamidine.
PentobarbitalThe metabolism of Mefloquine can be increased when combined with Pentobarbital.
PentoliniumThe therapeutic efficacy of Pentolinium can be decreased when used in combination with Mefloquine.
PerampanelThe therapeutic efficacy of Perampanel can be decreased when used in combination with Mefloquine.
PerflutrenMefloquine may increase the QTc-prolonging activities of Perflutren.
PerphenazineThe serum concentration of Perphenazine can be increased when it is combined with Mefloquine.
PhenacemideThe therapeutic efficacy of Phenacemide can be decreased when used in combination with Mefloquine.
PhenobarbitalThe metabolism of Mefloquine can be increased when combined with Phenobarbital.
PhenobarbitalThe serum concentration of Phenobarbital can be increased when it is combined with Mefloquine.
PhensuximideThe therapeutic efficacy of Phensuximide can be decreased when used in combination with Mefloquine.
PhenytoinThe metabolism of Mefloquine can be increased when combined with Phenytoin.
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Mefloquine.
PilocarpineThe risk or severity of adverse effects can be increased when Mefloquine is combined with Pilocarpine.
PimozideMefloquine may increase the QTc-prolonging activities of Pimozide.
PindololMefloquine may increase the bradycardic activities of Pindolol.
PipecuroniumThe therapeutic efficacy of Pipecuronium can be decreased when used in combination with Mefloquine.
PirenzepineThe therapeutic efficacy of Pirenzepine can be decreased when used in combination with Mefloquine.
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Mefloquine.
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Mefloquine.
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Mefloquine.
PosaconazoleThe metabolism of Mefloquine can be decreased when combined with Posaconazole.
PractololMefloquine may increase the bradycardic activities of Practolol.
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Mefloquine.
PrazosinThe serum concentration of Prazosin can be increased when it is combined with Mefloquine.
PrednicarbateThe risk or severity of adverse effects can be increased when Prednicarbate is combined with Mefloquine.
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Mefloquine.
PrednisoloneThe risk or severity of adverse effects can be increased when Prednisolone is combined with Mefloquine.
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Mefloquine.
PrednisoneThe risk or severity of adverse effects can be increased when Prednisone is combined with Mefloquine.
PregabalinThe therapeutic efficacy of Pregabalin can be decreased when used in combination with Mefloquine.
PregnenoloneThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Mefloquine.
PrimaquineThe risk or severity of adverse effects can be increased when Primaquine is combined with Mefloquine.
PrimaquineMefloquine may increase the QTc-prolonging activities of Primaquine.
PrimidoneThe therapeutic efficacy of Primidone can be decreased when used in combination with Mefloquine.
PrimidoneThe metabolism of Mefloquine can be increased when combined with Primidone.
ProcainamideMefloquine may increase the QTc-prolonging activities of Procainamide.
ProchlorperazineThe serum concentration of Prochlorperazine can be increased when it is combined with Mefloquine.
ProcyclidineThe therapeutic efficacy of Procyclidine can be decreased when used in combination with Mefloquine.
ProgabideThe therapeutic efficacy of Progabide can be decreased when used in combination with Mefloquine.
ProgesteroneThe serum concentration of Progesterone can be increased when it is combined with Mefloquine.
PromazineThe serum concentration of Promazine can be increased when it is combined with Mefloquine.
PromethazineThe serum concentration of Promethazine can be increased when it is combined with Mefloquine.
PropafenoneMefloquine may increase the QTc-prolonging activities of Propafenone.
PropanthelineThe therapeutic efficacy of Propantheline can be decreased when used in combination with Mefloquine.
PropranololMefloquine may increase the bradycardic activities of Propranolol.
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Mefloquine.
QuetiapineThe serum concentration of Quetiapine can be increased when it is combined with Mefloquine.
QuinidineThe risk or severity of adverse effects can be increased when Quinidine is combined with Mefloquine.
QuinidineThe therapeutic efficacy of Quinidine can be decreased when used in combination with Mefloquine.
QuinineThe risk or severity of adverse effects can be increased when Quinine is combined with Mefloquine.
QuinineThe serum concentration of Quinine can be increased when it is combined with Mefloquine.
RanitidineThe serum concentration of Ranitidine can be increased when it is combined with Mefloquine.
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Mefloquine.
RanolazineThe metabolism of Mefloquine can be decreased when combined with Ranolazine.
RapacuroniumMefloquine may decrease the neuromuscular blocking activities of Rapacuronium.
remacemideThe therapeutic efficacy of remacemide can be decreased when used in combination with Mefloquine.
ReserpineThe serum concentration of Reserpine can be increased when it is combined with Mefloquine.
RifabutinThe metabolism of Mefloquine can be increased when combined with Rifabutin.
RifampicinThe metabolism of Mefloquine can be increased when combined with Rifampicin.
RifampicinThe serum concentration of Rifampicin can be increased when it is combined with Mefloquine.
RifapentineThe metabolism of Mefloquine can be increased when combined with Rifapentine.
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Mefloquine.
RiluzoleThe therapeutic efficacy of Riluzole can be decreased when used in combination with Mefloquine.
RimexoloneThe risk or severity of adverse effects can be increased when Rimexolone is combined with Mefloquine.
RisperidoneThe serum concentration of Risperidone can be increased when it is combined with Mefloquine.
RitonavirThe metabolism of Mefloquine can be decreased when combined with Ritonavir.
RitonavirThe serum concentration of Ritonavir can be increased when it is combined with Mefloquine.
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Mefloquine.
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Mefloquine.
RufinamideThe therapeutic efficacy of Rufinamide can be decreased when used in combination with Mefloquine.
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Mefloquine.
SaquinavirMefloquine may increase the QTc-prolonging activities of Saquinavir.
SaquinavirThe metabolism of Mefloquine can be decreased when combined with Saquinavir.
ScopolamineThe therapeutic efficacy of Scopolamine can be decreased when used in combination with Mefloquine.
Scopolamine butylbromideThe therapeutic efficacy of Scopolamine butylbromide can be decreased when used in combination with Mefloquine.
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Mefloquine.
SildenafilThe metabolism of Mefloquine can be decreased when combined with Sildenafil.
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Mefloquine.
SiltuximabThe serum concentration of Mefloquine can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Mefloquine can be increased when it is combined with Simeprevir.
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Mefloquine.
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Mefloquine.
SolifenacinThe therapeutic efficacy of Solifenacin can be decreased when used in combination with Mefloquine.
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Mefloquine.
SotalolMefloquine may increase the bradycardic activities of Sotalol.
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Mefloquine.
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Mefloquine.
St. John's WortThe serum concentration of Mefloquine can be decreased when it is combined with St. John's Wort.
StiripentolThe serum concentration of Mefloquine can be increased when it is combined with Stiripentol.
StiripentolThe therapeutic efficacy of Stiripentol can be decreased when used in combination with Mefloquine.
SuccinylcholineThe serum concentration of Succinylcholine can be increased when it is combined with Mefloquine.
SulfisoxazoleMefloquine may increase the QTc-prolonging activities of Sulfisoxazole.
SulfisoxazoleThe metabolism of Mefloquine can be decreased when combined with Sulfisoxazole.
SULTHIAMEThe therapeutic efficacy of SULTHIAME can be decreased when used in combination with Mefloquine.
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Mefloquine.
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Mefloquine.
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Mefloquine.
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Mefloquine.
TelaprevirThe metabolism of Mefloquine can be decreased when combined with Telaprevir.
TelaprevirThe serum concentration of Telaprevir can be increased when it is combined with Mefloquine.
TelavancinMefloquine may increase the QTc-prolonging activities of Telavancin.
TelithromycinMefloquine may increase the QTc-prolonging activities of Telithromycin.
TelithromycinThe metabolism of Mefloquine can be decreased when combined with Telithromycin.
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Mefloquine.
TetrabenazineMefloquine may increase the QTc-prolonging activities of Tetrabenazine.
ThiethylperazineThe serum concentration of Thiethylperazine can be increased when it is combined with Mefloquine.
ThiopentalThe therapeutic efficacy of Thiopental can be decreased when used in combination with Mefloquine.
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Mefloquine.
TiagabineThe therapeutic efficacy of Tiagabine can be decreased when used in combination with Mefloquine.
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Mefloquine.
TiclopidineThe metabolism of Mefloquine can be decreased when combined with Ticlopidine.
TiletamineThe therapeutic efficacy of Tiletamine can be decreased when used in combination with Mefloquine.
TimololMefloquine may increase the bradycardic activities of Timolol.
TiotropiumThe therapeutic efficacy of Tiotropium can be decreased when used in combination with Mefloquine.
TixocortolThe risk or severity of adverse effects can be increased when Tixocortol is combined with Mefloquine.
TizanidineThe therapeutic efficacy of Tizanidine can be decreased when used in combination with Mefloquine.
TocilizumabThe serum concentration of Mefloquine can be decreased when it is combined with Tocilizumab.
TolterodineThe therapeutic efficacy of Tolterodine can be decreased when used in combination with Mefloquine.
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Mefloquine.
TopiramateThe therapeutic efficacy of Topiramate can be decreased when used in combination with Mefloquine.
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Mefloquine.
ToremifeneThe serum concentration of Toremifene can be increased when it is combined with Mefloquine.
tramiprosateThe therapeutic efficacy of tramiprosate can be decreased when used in combination with Mefloquine.
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Mefloquine.
TriamcinoloneThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Mefloquine.
TrifluoperazineThe serum concentration of Trifluoperazine can be increased when it is combined with Mefloquine.
TriflupromazineThe serum concentration of Triflupromazine can be increased when it is combined with Mefloquine.
TrihexyphenidylThe therapeutic efficacy of Trihexyphenidyl can be decreased when used in combination with Mefloquine.
TrimethadioneThe therapeutic efficacy of Trimethadione can be decreased when used in combination with Mefloquine.
TrimethaphanThe therapeutic efficacy of Trimethaphan can be decreased when used in combination with Mefloquine.
TropicamideThe therapeutic efficacy of Tropicamide can be decreased when used in combination with Mefloquine.
TrospiumThe therapeutic efficacy of Trospium can be decreased when used in combination with Mefloquine.
TubocurarineThe therapeutic efficacy of Tubocurarine can be decreased when used in combination with Mefloquine.
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Mefloquine.
UmeclidiniumThe therapeutic efficacy of Umeclidinium can be decreased when used in combination with Mefloquine.
Valproic AcidThe therapeutic efficacy of Valproic Acid can be decreased when used in combination with Mefloquine.
ValpromideThe therapeutic efficacy of Valpromide can be decreased when used in combination with Mefloquine.
VandetanibMefloquine may increase the QTc-prolonging activities of Vandetanib.
VareniclineThe risk or severity of adverse effects can be increased when Mefloquine is combined with Varenicline.
VecuroniumThe therapeutic efficacy of Vecuronium can be decreased when used in combination with Mefloquine.
VemurafenibMefloquine may increase the QTc-prolonging activities of Vemurafenib.
VenlafaxineThe metabolism of Mefloquine can be decreased when combined with Venlafaxine.
VenlafaxineThe serum concentration of Venlafaxine can be increased when it is combined with Mefloquine.
VerapamilThe metabolism of Mefloquine can be decreased when combined with Verapamil.
VerapamilThe serum concentration of Verapamil can be increased when it is combined with Mefloquine.
VigabatrinThe therapeutic efficacy of Vigabatrin can be decreased when used in combination with Mefloquine.
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Mefloquine.
VincristineThe serum concentration of Vincristine can be increased when it is combined with Mefloquine.
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Mefloquine.
VoriconazoleThe metabolism of Mefloquine can be decreased when combined with Voriconazole.
ZaleplonThe therapeutic efficacy of Zaleplon can be decreased when used in combination with Mefloquine.
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Mefloquine.
ZiprasidoneThe metabolism of Mefloquine can be decreased when combined with Ziprasidone.
ZiprasidoneMefloquine may increase the QTc-prolonging activities of Ziprasidone.
ZonisamideThe therapeutic efficacy of Zonisamide can be decreased when used in combination with Mefloquine.
ZuclopenthixolMefloquine may increase the QTc-prolonging activities of Zuclopenthixol.
Food Interactions
  • Avoid alcohol.
  • Take with a full glass of water.
  • Take with food.

Targets

1. Fe(II)-protoporphyrin IX
Kind
Small molecule
Organism
Plasmodium falciparum
Pharmacological action
yes
Actions
antagonist
References
  1. Fitch CD: Ferriprotoporphyrin IX, phospholipids, and the antimalarial actions of quinoline drugs. Life Sci. 2004 Mar 5;74(16):1957-72. [PubMed:14967191 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Oxygen transporter activity
Specific Function:
Involved in oxygen transport from the lung to the various peripheral tissues.
Gene Name:
HBA1
Uniprot ID:
P69905
Molecular Weight:
15257.405 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Identical protein binding
Specific Function:
Receptor for adenosine. The activity of this receptor is mediated by G proteins which activate adenylyl cyclase.
Gene Name:
ADORA2A
Uniprot ID:
P29274
Molecular Weight:
44706.925 Da
References
  1. Gillespie RJ, Adams DR, Bebbington D, Benwell K, Cliffe IA, Dawson CE, Dourish CT, Fletcher A, Gaur S, Giles PR, Jordan AM, Knight AR, Knutsen LJ, Lawrence A, Lerpiniere J, Misra A, Porter RH, Pratt RM, Shepherd R, Upton R, Ward SE, Weiss SM, Williamson DS: Antagonists of the human adenosine A2A receptor. Part 1: Discovery and synthesis of thieno[3,2-d]pyrimidine-4-methanone derivatives. Bioorg Med Chem Lett. 2008 May 1;18(9):2916-9. doi: 10.1016/j.bmcl.2008.03.075. Epub 2008 Mar 30. [PubMed:18406614 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Identical protein binding
Specific Function:
Esterase with broad substrate specificity. Contributes to the inactivation of the neurotransmitter acetylcholine. Can degrade neurotoxic organophosphate esters.
Gene Name:
BCHE
Uniprot ID:
P06276
Molecular Weight:
68417.575 Da
References
  1. Lim LY, Go ML: The anticholinesterase activity of mefloquine. Clin Exp Pharmacol Physiol. 1985 Sep-Oct;12(5):527-31. [PubMed:3878759 ]
  2. Zhou C, Xiao C, McArdle JJ, Ye JH: Mefloquine enhances nigral gamma-aminobutyric acid release via inhibition of cholinesterase. J Pharmacol Exp Ther. 2006 Jun;317(3):1155-60. Epub 2006 Feb 24. [PubMed:16501066 ]
  3. McArdle JJ, Sellin LC, Coakley KM, Potian JG, Quinones-Lopez MC, Rosenfeld CA, Sultatos LG, Hognason K: Mefloquine inhibits cholinesterases at the mouse neuromuscular junction. Neuropharmacology. 2005 Dec;49(8):1132-9. Epub 2005 Aug 2. [PubMed:16081111 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Oxygen binding
Specific Function:
Catalyzes the formation of aromatic C18 estrogens from C19 androgens.
Gene Name:
CYP19A1
Uniprot ID:
P11511
Molecular Weight:
57882.48 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Serine hydrolase activity
Specific Function:
Terminates signal transduction at the neuromuscular junction by rapid hydrolysis of the acetylcholine released into the synaptic cleft. Role in neuronal apoptosis.
Gene Name:
ACHE
Uniprot ID:
P22303
Molecular Weight:
67795.525 Da
References
  1. Lim LY, Go ML: The anticholinesterase activity of mefloquine. Clin Exp Pharmacol Physiol. 1985 Sep-Oct;12(5):527-31. [PubMed:3878759 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Fujita R, Ishikawa M, Takayanagi M, Takayanagi Y, Sasaki K: Enhancement of doxorubicin activity in multidrug-resistant cells by mefloquine. Methods Find Exp Clin Pharmacol. 2000 Jun;22(5):281-4. [PubMed:11031728 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23